Therefore, gaining more evidence of the role of HIF-1α/VEGF and related signaling pathways in GBM progression will further support the use of their immunophenotypes in prognosis and the effectiveness of the treatment of GBM. This evidence concerns the gene VEGFA and glioblastoma.